

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

17 January 2023

Investor presentation at USA Maxim Group Healthcare IT Virtual Conference

Respiri Limited (ASX:RSH, OTCQB:RSHUF) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce that the Company’s Managing Director Marjan Mikel is invited as a presenter at the USA Maxim Group Healthcare IT Virtual Conference (the “**Conference**”) to speak on the topic of “Improving respiratory care and reducing costs with technology and remote patient monitoring”.

The Virtual Conference is presented by Maxim Group and is to be held on 25th January and 26th January 2023.

Marjan Mikel will be speaking on the above-mentioned topic on 26th January 2023 at 8am AEDT.

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel

CEO & Managing Director

Respiri Limited

P: +61 408 462 873

E: marjan@respiri.co

Mr Nicholas Smedley

Executive Chairman

Respiri Limited

P: +61 447 074 160

E: nicholas@respiri.co

This announcement has been approved by the Board of Respiri Limited

About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website www.respiri.co/au
